144
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

ORCID Icon, , ORCID Icon, &
Pages 8219-8230 | Published online: 02 Nov 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (9)